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    AMP-activated kinase (AMPK) and silent mating-type information 
regulator 2 homolog 1 (SIRT1) are the two representative enzymes involved 
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in energy homeostasis. Concomitant action of AMPK and SIRT1 mediates 
various beneficial effects including suppression of Alzheimer’s disease (AD) 
pathophysiology. Even though these two enzymes activate each other, 
metformin, the most widely prescribed anti-diabetic drug, has shown to exert 
neurotoxic effects via AMPK activation. Therefore, I aimed to examine the 
effect of metformin on neuronal SIRT1 activity, as well as on AMPK. 
Normally, metformin-induced AMPK activation would result in concomitant 
SIRT1 activation via activating AMPK/nicotinamide phosphoribosyltrans-
ferase (Nampt)/nicotinamide adenine dinucleotide (NAD) pathway. 
However, I found that metformin could not activate neuronal SIRT1 despite 
AMPK activation. Rather, metformin reduced the levels of Nampt and NAD, 
which accounts for the failure of SIRT1 activation. Metformin-induced 
AMPK activation increased the levels of beta-site amyloid precursor protein 
cleavage enzyme 1 (BACE1) and secreted beta-amyloid (Aβ). In addition, 
metformin-induced Nampt suppression was associated with decreased 
expression of tumor necrosis factor alpha converting enzyme (TACE) which 
promotes non-amyloidogenic pathway. These adverse effects of metformin 
were also identified in the brains of diabetic db/db mice. Overexpression of 
Nampt rescued metformin-induced neurotoxicity in vitro. Also, donepezil 
treatment reversed the negative effects of metformin in vitro and in vivo, by 
promoting Nampt/NAD pathway. Data from the current study implicate the 
importance of the role of Nampt in regulating amyloidogenesis; AMPK 
activation by metformin might be neurotoxic because it could not induce 
concomitant action of AMPK and SIRT1 owing to the lack of Nampt 
	 3	
involvement in the brain contrasted with other peripheral tissues. Co-
treatment of donepezil could be a proper measure to protect the brain from 
potential risk of promoting AD pathogenesis in diabetic patients taking 
metformin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
key words: Nampt, SIRT1, AMPK, Aβ, Amyloidogenesis, Metformin, 
BACE1, TACE, Donepezil  
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I. INTRODUCTION 
 
1. Nicotinamide phosphotransferase (Nampt) 
 
    Nampt has been referred to as pre-B-cell colony-enhancing factor (PBEF) 
or visfatin. Originally, this was first discovered as a putative cytokine, and so 
gained the name as PBEF.1 In 2002, Rongvaux et al. first identified that 
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PBEF has a key role of nicotinamide adenine dinucleotide (NAD) 
biosynthesis.2 After that, it was reported that PBEF gene could encode a 
Nampt. And also, another function of Nampt/PBEF was identified as a 
visceral fat-derived hormone (visfatin),3 so this protein has been called as 
Nampt, PBEF or visfatin after all. 
     In NAD biosynthesis, Nampt is the rate-limiting enzyme converting 
nicotinamide (NAM) to nicotinamide mononucleotide (NMN).4,5 NAD has 
fundamental role in energy metabolism such as redox metabolism in citric 
acid cycle and oxidative phosphorylation.6,7 NAD is required in DNA repair 
and telomere maintenance in ADP-ribose transfer reactions via poly(ADP-
ribose) polymerases (PARP).8 NAD is also consumed by histone deacetylase 
action of silent mating type information regulation 2 homolog 1 (sirtuin or 
SIRT1),9 and sufficient NAD level is thus required for normal functioning of 
SIRT1. NAD biosynthesis have two metabolic pathways, one is de novo 
pathway and another is NAD salvage pathway (Fig. 1). In de novo pathway, 
NAD is made from tryptophan through several cascade steps.10 Separately 
de novo pathway, NAD salvage pathway is operated in cell organisms, 
which make and use precursors of NAD.11 Especially, NAD salvage pathway 
was also known as an essential mechanism for NAD supply in humans. In 
NAD salvage pathway, NAD is transferred to NAM, which then is converted 
to NMN by Nampt. If action of Nampt is insufficient in this step, NAD 
would be only exhausted, and after all, cellular respiration, oxidative 
phosphorylation and other NAD-dependent mechanisms will be 
disintegrated.10,11  
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Figure 1. NAD biosynthetic pathway in mammals. There are two 
pathways in NAD biosynthesis. One is de novo pathway using 
tryptophan or nicotinic acid, another is NAD salvage pathway which is 
controlled by Nampt, the rate-limiting enzyme of NAD synthesis. 
NaMN, nicotinic acid mononuclotide; NAM, nicotinamide; NMN, 
nicotinamide mononucleotide. 
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2. Alzheimer`s Disease 
 
    Alzheimer`s disease (AD) is the most common form of senile dementia,12 
constituting about 70% of all cases. According to World Alzheimer Report 
2014, there are estimated 44 million patients with dementia worldwide. And 
the number of AD patients is predicted to increase more than triple by 2050 
so that 1 of 85 people would suffer from AD.13 
    AD is a neurodegenerative disease, leading to memory loss, cognitive and 
functional decline and death. The molecular mechanisms of AD were 
investigated in many previous studies. Nevertheless, there has been no cure 
for AD yet; there are just a few mitigating treatments at the moment. 
Additionally, overt AD pathology can only be found once neurodegenerative 
processes are progressed to a degree. Therefore, the preventive healthcare 
via understanding AD mechanism is the key role of reducing and protecting 
AD. There are several hypotheses for AD pathogenesis, among which are 
beta-amyloid (Aβ),14 tau15 and cholinergic hypothesis.16  
 
A. Amyloid cascade hypothesis 
     Extracellular amyloid plaque (also called as senile plaque) in the central 
nervous system is the hallmark of AD pathology.17 Amyloid plaques lead to 
inflammatory responses in neurons and tau pathology,18,19 another etiological 
factors of AD. Plaques are formed by accumulation of Aβ peptides, which 
are cleaved fragments of amyloid precursor protein (APP).14  
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     The enzymes associated with APP cleavage are α-secretase, β-secretase 
and γ-secretase. APP cleavage pathways are classified according to two 
cleavage enzymes, α-secretase and β-secretase. These two enzymes cleave 
each specific sequential sites of APP, making different fragments of APP 
with another cleavage enzyme, γ -secretase. First, amyloidogenic pathway is 
composed of two cleavage steps. APP is cleaved by beta-site amyloid 
precursor protein cleavage enzyme 1 (BACE1), which makes sAPP-β and 
C99. Then, C99 is digested to Aβ and amyloid precursor protein intracellular 
cytoplasmic/c-terminal domain (AICD) by γ-secretase (Fig. 2).20 On the 
other hand, α-secretase induces non-amyloidogenic pathway through 
Figure 2. Amyloidogenic and non-amyloidogenic pathways. There are 
two pathways in amyloid cascade, and these pathways are occurred via α-
secretase and β-secretase competitively.  
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cleaving different site of APP (Fig. 2). A disitegrin and metalloproteinase 
(ADAM) family was known as the representative α-secretase, and ADAM10 
and tumor necrosis factor alpha converting enzyme (TACE, also known as 
ADAM17) are the typical α-secretases.21,22  
     Amyloid plaque is found in early stage of AD, and Aβ peptide oligomers 
themselves are the cause of acute synaptotoxic effects.14,23 In these regard, 
Aβ has been a priority target of AD therapeutic strategies such as modulation 
of Aβ production, inhibition of Aβ aggregation and enhancement of Aβ 
degradation.  
 
B. Tau hypothesis 
     Another hallmark of AD is neurofibrillary tangles (NFTs), which are 
formed by hyperphosphorylated tau proteins (Fig. 3).15,24 Tau, soluble 
microtubule-associated protein, is found mostly in, neurons than other 
peripheral tissues. Main functions of tau are the stabilization of axonal 
microtubules and the growth factor of cytoskeletal elements.  
     NFTs lead to damage of cytoplasmic functions and interruption of axonal 
transport, and it brings neuronal cell about death in the end. Actually, 
hyperphosphorylated tau is the pathology in a number of other neuronal 
disorders such as corticobasal degeneration, motor neuron diseases and 
traumatic brain injury.25 Additionally, NFTs via hyperphosphorylated tau is 
found in frontotemporal dementia, and also cognitive dysfunction, which is 
the typical symptom of AD, is correlated with NFTs.26 Furthermore, recent 
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studies revealed that tau was secreted extracellularly via the release of 
exosome in AD.27 
     Tau protein is known as the factor of various neuronal diseases, however 
the correlation of tau and AD is investigated in recent studies.28 Also, it 
revealed that amyloid plaques increased tau hyperphosporylation via 
AMPK.18 So tau pathology has received attention as much as Aβ in AD 
pathogenesis. 
 
 
 
Figure 3. Tau pathway in AD pathogenesis. Soluble tau protein is 
changed to insoluble form via hyperphosphorylation and aggregation 
through cascade pathway. After all, tau oligomer is changed to NFTs 
which lead to neurodegeneration.  
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C. Cholinergic hypothesis 
     In 1970s, Drachman et al. showed that synthesis of acetylcholine (Ach) 
was deficient in the brains of AD patients, and that this shortage led to 
neurochemical abnormality via presynaptic cholinergic deficit.29 Following 
this preliminary study, “cholinergic hypothesis of AD” was established based 
on emerging role of Ach in learning and memory system.30 
     Ach is a neurotransmitter which is involved in cognitive function. 
Actually, deficits of Ach and cholinergic transmission have been also found 
in various neurodegenerative disorder.31 Besides, other study investigated 
that Ach level was deficient in the brain of normally aging animals. So, 
cholinergic hypothesis was controversial regarding AD pathogenesis. 
However, recent studies established that Ach was strongly related with AD 
pathogenesis, especially Aβ synthesis. The metabolism of Aβ was regulated 
by stimulation of muscarinic or nicotinic cholinergic receptors. And also, it 
was found that cholinergic deficits led to be a secondary effect of Aβ 
toxicity.16,32 
    Cholinergic deficiency may not be a direct factor but could be a metabolic 
reason for initiation of amyloid cascade pathway. On this basis, increase in 
synthesis and synaptic activity of Ach was focused on as a therapeutic 
strategy on neuropharmacology,32 and cholinersterase inhibitors such as 
donepezil, rivastigmine and galantamine, are being used for the treatment  of 
AD.33,34  
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3. AD and Diabetes 
 
    According to the National Statistical Office (NSO), the world already has 
entered into aging society, and is progressing towards super-aged society. An 
aging society incurs many severe problems, which are the labor shortage, 
slowdown of economic growth, and increase of support expense. In 
particular, elderly people may be prone to various diseases, and this is the 
major cause of increment of support expense. Cognitive and metabolic 
disorders are among the most representative geriatric diseases, such as AD 
and diabetes.35 Intriguingly, many studies have suggested that AD and 
diabetes were correlated from epidemiologic and mechanistic 
perspective.36,37  
 
A. Epidemiologic interaction 
     Diabetes, especially Type 2 diabetes mellitus (T2DM), is connected with 
AD, and many previous studies showed that diabetes is a high risk factor of 
AD and other dementias.35,36 However, from other previous epidemiologic 
findings, correlation of AD and diabetes has been controversial. Some 
investigators showed that although diabetes had increased risk for 
development of AD and dementia, the effects of risk factors, especially 
insulin resistance, were independent rather than linked between dementia 
and AD in longitudinal survey.38 Also in other study, people who had lower 
body mass index (BMI) were faced in higher risk for developing AD than 
higher BMI.39 
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B. Mechanistic interaction 
     Mechanistic correlation between AD and T2DM has been studied by 
many investigators. Actually, T2DM and obesity share a lot of factors 
increasing dementia risk, such as peripheral insulin resistance, oxidative 
stress, increment of pro-inflammatory cytokines, chronic hyperglycemia and 
cerebral microvascular disease.39,40 However, direct correlation of T2DM 
and AD was controversial via some studies.41,42  
     A previous study showed that old adults with T2DM had some risk 
factors of AD, including hippocampal atrophy, and lacunes in brain via 
neuroimaging. Also, another study showed that T2DM was occurred more 
frequently in AD patients than non-AD patients.41 However, other study 
investigated that T2DM and increase of NFTs were not correlated, and 
suggested that T2DM was not sufficient factor of increase of AD.42 
     In a recent study, correlation between T2DM and AD was shown 
regarding to histopathological, molecular and biochemical abnormalities 
using high-fat diet feeding mice and human studies.43 Moreover, these 
investigators referred AD as “type 3 diabetes mellitus” and asserted that AD 
might be treatable, preventable, or curable by anti-diabetes medications. 
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4. Metformin  
 
    Metformin has been used as first-line medication for T2DM for over 50 
yr.44 Metformin has some advantages including safety profile and weight 
reduction effects in cardiovascular disease.45,46 Additionally, metformin has 
shown some possibilities to reduce cancer risk in diabetic patients.47 It has 
been also used in other insulin resistance diseases such as gestational 
diabetes and polycystic ovary syndrome.48,49 On the basis of these 
advantages and various usages, metformin was selected as a WHO Model 
List of Essential Medicines by World Health Organization (WHO). 
 
A. History and molecular action 
     Metformin belongs to the biguanide class which was used as folk 
medicine in the past. In 1922, metformin was first come up in a scientific 
report as a product of synthesis of N, N-dimethylguanidine via reaction of 
dimethylamine hydrochloride and 2-cyanoguanidine with heating (Fig. 4-
A).50,51 However, for over 30 years, metformin had been forgotten because of 
insulin usage for diabetes. In 1957, metformin was first used for humans 
having diabetes as named “Glucophage” by French physician, Jean Sterne. 
After that, metformin was permitted usage for treatment of diabetes by 
British National Formulary in 1958, and approved by Canada in 1972. In 
1994, metformin finally was recognized by U.S. Food and Drug 
Administration (FDA).52 
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     Metformin suppresses blood sugar level by gluconeogenesis inhibition 
and reducing hepatic glucose output in terms of anti-diabetic effects,50 and 
metformin is also known as AMPK activator in energy metabolic aspects. 
Guanidine-containing complexes had been known for reducing 
hyperglycemia before metformin was developed, however they had a 
toxicity.53 Many pioneer investigators, who were interested in the guanidine 
effects, tried to reduce toxicity, and finally found the methods of suppressing 
the toxicity via composed of two guanidines. Metformin was found before 
the generation of target-specific drug discovery, so its mechanism has been 
investigated since clinical usage, and is currently underway. Up to date, a 
major anti-hyperglycemic mechanism of metformin in liver cells, including 
that of other biguanides, has been known as inhibition of mitochondrial 
electron transport chain, complex I, which leads to reduction in ATP: AMP 
ratios regarding cellular energy depletion.54,55 Increase of AMP concentration 
inhibits directly gluconeogenesis, and also suppresses activation of glucagon 
via inhibition of adenylate cyclase.56 This cascade pathway is the main anti-
diabetic mechanism of metformin. Additionally, increment of AMP activates 
AMPK, and it leads many positive effects in energy metabolism (Fig. 4-B). 
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Figure 4. Synthesis and molecular action of Metformin. (A) 
Metformin was synthesized via reaction of dimethylamine and 2-
cyanoguanidine. (B) Metformin activates AMPK and inhibits 
gluconeogenesis and activation of glucagon via suppressing of 
mitochondria complex I.  
 
	 17	
B. Metformin and AD 
     As mentioned above, metformin activates AMPK via increase of AMP 
concentration in hepatocytes. AMPK activation is critical mechanism of 
energy metabolic regulation, and previous studies showed that metformin-
induced AMPK activation modulated various effects of AMPK-dependent 
energy metabolic pathways; decrease of sterol regulatory element-binding 
protein-1 (SREBP-1),57 suppression of lipid synthesis in liver58 and increase 
of fatty acid oxidation in hepatocytes.54  
     On the other hand, in 2009, it was reported that metformin induced 
adverse effects on AD pathway.59 Chen et al. demonstrated that metformin 
increased Aβ production via AMPK activation in vitro and in vivo. They 
elucidated that metformin-induced AMPK activation increased the activity 
of BACE1 promoter, causing increase in Aβ levels in the brain. Given the 
general expectation that anti-diabetic medication may exert beneficial effects 
on AD pathogenesis, the findings from Chen et al. study have raised issues 
on the role of AMPK in AD pathogenesis. 
 
 
5. AMPK and SIRT1 
 
A. AMPK 
     In neurons, AMPK is known as the important factor for maintenance of 
energy balance and healthy aging. Caloric restriction (CR) is well known to 
extend lifespan, and such effect was linked to increase of AMPK activity.60 
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Moreover, AMPK increases the autophagy via the mammalian target of 
rapamycin (mTOR) pathway, and enhances stress resistance through 
reducing of forkhead box protein O1 (FOXO1) and nuclear factor erythroid 
2-related factor 2 (Nrf2) activity. AMPK is also regarded as a critical target 
molecules to rescue or prevent neurodegeneration diseases.61 Resveratrol, a 
kind of natural polyphenol, was known to exert a positive effect on 
Parkinson`s disease, amyotrophic lateral sclerosis, and AD through AMPK 
activation. Especially, resveratrol attenuated AD by modulating Aβ- and tau-
related pathogenesis via AMPK.62 
 
B. SIRT1 
     In a previous study with resveratrol, Price et al. showed another key 
factor to gain therapeutic effects other than AMPK activation, it was SIRT1. 
It was known as a deacetylase enzyme.63 SIRT1 is linked to numerous 
cellular processes, including gene silencing, DNA repair, metabolic 
regulation, and suppression of neurodegeneration or aging via both direct 
and indirect deacetylation of various transcription factors.64,65,66 In previous 
studies, SIRT1 was shown to have beneficial effects against AD under CR. 
In SIRT1-deficient condition, calorie restricted mice did not reduce Aβ 
plaque.67 In contrast, SIRT1 activation led to prevent amyloidogenesis in CR 
condition mice.68 Also, SIRT1 overexpression mice were rescued from AD 
phenotype similar to CR condition.69  
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C. Concomitant action of AMPK and SIRT1 
     Recent investigations have revealed that concomitant action of AMPK 
and SIRT1 is critical for their beneficial effects on metabolism since 
experimental manipulations to activate only either of the two have shown 
failures in deriving expected outcomes.70,71 Nevertheless, AMPK and SIRT1 
normally activate each other. Thus, activation of either of the two would be 
expected to induce their concomitant action. Indeed, resveratrol, as a SIRT1 
activator, has shown to activate AMPK via SIRT1/liver kinase B1 (LKB1) 
pathway in hepatocytes (Fig. 5).62,72 5-Aminoimidazole-4-carboxamide 
ribonucleotide (AICAR), an AMPK activator, is known to activate SIRT1 
via Nampt/NAD pathway or promoting beta-oxidation (Fig. 5).73 However, 
such a dynamic relationship between AMPK and SIRT1 has not been fully 
elucidated in neurons compared to other peripheral tissues. 
Figure 5. The scheme of concomitant action of AMPK-SIRT1. Many 
recent studies show that AMPK and SIRT1 activate each other via Nampt 
and LKB1, respectively. Resultantly achieved, concomitant activation 
lead to beneficial effects on metabolism in several peripheral tissues. 
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D. AMPK, SIRT1 and Nampt 
     Nampt is the key molecule of NAD synthesis, and thus SIRT1, NAD+ 
dependent deacetylase, is directly affected by Nampt.74 Additionally, SIRT1 
converts NAD to NAM in NAD salvage pathway, thus depletion of Nampt 
leads to lack of NMN directly, and shortage of NAM indirectly.9  Moreover, 
previous study showed that AMPK could activate SIRT1 using NAD.73 
Therefore, Nampt may be a critical mediator of beneficial effects on 
metabolism of concomitant action of AMPK-SIRT1. 
 
 
6. Aims of this study 
 
    Metformin has been still first line of anti-diabetic medication, and this 
trend may continue for a while. Moreover, diabetes is a chronic disease 
which needs life-long cares and treatments. So, a potential of metformin to 
induce AD pathogenesis is a highly serious problem to patients with diabetes 
who may have already a tentative risk of AD. 
 
    AMPK activation is the pivotal mechanism of metformin, and thus is 
thought to be related to various beneficial effects of this drug. According to 
recent findings, however, activation of neuronal AMPK might have a 
negative, rather than positive, role in AD pathogenesis. Neuronal AMPK 
activation by various compounds including metformin has been shown to 
induce BACE1 upregulation and synaptotoxicity via AMPK-dependent tau 
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phosphorylation.18,28 These findings are highly unexpected because AMPK 
has been known to increase SIRT1 activity through Nampt/NAD pathway at 
least in peripheral tissues,73,75 and concomitant action of AMPK and SIRT1 
has been shown to suppress AD pathologies.70 However, to my best 
knowledge, effects of metformin on SIRT1 activity have not been directly 
examined in neuronal tissue, which is known to have relatively low levels of 
Nampt expression and NAD depletion.76,77  
 
    Here I show that metformin increased activity of neuronal AMPK, but 
failed to induce concomitant activation of SIRT1 in neuronal tissues. Such 
failure in SIRT1 activation was attributed, at least in part, to metformin-
induced downregulation of Nampt which mediates AMPK-dependent SIRT1 
activation via the NAD salvage pathway. In addition, Metformin-induced 
suppression of Nampt was found to decrease the expression of TACE which 
decreases Aβ production by promoting non-amyloidogenic pathways.21 
Interestingly, the most widely prescribed anti-dementic drug, donepezil, 
reversed such adverse effects of metformin by activating Nampt and thus 
rendering the concomitant activation of AMPK and SIRT1.  
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II. MATERIALS AND METHODS 
 
1. Cell culture and transfection 
 
     Neuro2A (from ATCC, Manassas, VA, USA), the mouse neuroblastoma 
cell lines, was grown in Dulbecco`s Modified Eagle`s Medium (GE 
healthcare, South Logan, UT, USA) with 10% fetal bovine serum (GE 
healthcare) in a humidified incubator containing 5% CO2, at 37℃. NAMPT 
and SIRT1 DNA (Addgene, Cambridge, MA, USA) were amplified by PCR 
and sub-cloned into pcDNA3.1 vector.  Neuro2A cells were transfected with 
cloned DNA supplement 10ug jetPRIME (Polyplus Transfection, Illkirch, 
France) for 24hr before the start of the experimental incubations. For stable 
cell line, Human-APP695, sub-cloned into pcDNA3.1 vector, was transfected 
into Neuro2A cells. And transfected cells were selected geneticin (200ug/ml, 
Gibco, Grand Island, NY, USA) for 48hr, then only selected cells were sub-
cultured by DMEM-OptiMEM (Gibco) mixed media supplemented 10% 
fetal bovine serum with 200ug/ml geneticin. Stable cell line was fast 
freezing and stocked in liquid nitrogen tank. 
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2. Animal experiments 
 
     Eight-week-old male db/db mice (Central lab, Animal Inc. Seoul, Korea) 
were treated metformin (2mg/ml in drinking water)59 and donepezil 
(5mg/kg) ad libitum. Water intake and body weight of the animals were 
monitored every day. After 7days of treatment, mice were sacrificed and 
their hippocampi were snap-frozen on dry ice, and used for Western blot 
analysis and qRT-PCR. All mice were housed with a 12hr light-dark cycle in 
Yonsei University College of Medicine Animal Care Facilities approved 
Association for Assessment and Accreditation of Laboratory Animal Care. 
All animal experiments were approved by the Animal Care Committee of 
Yonsei University college of Medicine with NIH guidelines.   
 
 
3. Reagents and antibodies 
 
     Metformin (1,1-bimethylbiguanide hydrochloride) and FK866 were 
purchased from Sigma Aldrich (St. Louis, MO, USA). Compound C, an 
AMPK inhibitor, was from Merck Millipore (Darmstadt, Germany). Anti-
BACE1, pAMPK (Thr172), AMPK, HRP-rabbit and HRP-mouse antibodies 
were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-
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SIRT1 antibody was from Merck Millipore. Anti- TACE, ADAM10, 
GAPDH, and β-actin antibodies were from Santa Cruz Biotechnology 
(Dallas, TX, USA). 
 
 
4. Western blot analysis 
 
     Cells were lysed in ice-cold RIPA buffer (Thermo, Rockford, Illinois, 
USA), addition of 1mM NaF, 1mM Na3VO4, 1.15mM Na2MoO4, 2mM 
C3H2N4, 4mM C4H4Na2O6·2H2O (Sigma Aldrich), and complete protease 
inhibitor cocktail (Roche, Indianapolis, Indiana, USA). All lysates were 
measured with the BCA Protein Assay Kit (Thermo). I made samples with 
equal amounts of protein and boiled at 97℃ for 10min to denaturation of 
protein structure. Each protein sample was separated on 4-12% bis-Tris gel 
or 10% Tris-Glycine gel for the molecular weight of the protein of interest. 
And proteins were transferred to nitrocellulose membranes (GE healthcare) 
using wet transfer systems (Mighty Small Transphor, GE healthcare). 
Finally, protein bands were detected with Amersham ECL western blotting 
reagent (GE Healthcare) using the LAS mini system (Fuji Film, Tokyo, 
Japan). All band intensities were measured using Image J software 
(http://rsbweb.nih.gov/ij/). 
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5. Quantitative Real-time PCR 
 
     Total RNA was extracted using the RNeasy mini kit (Qiagen, Venlo, 
Netherlands) according to the manufacturer’s instructions. Equal amounts of 
RNA were reverse transcribed using Tetro cDNA Synthesis Kit (Bioline, 
London, UK). Quantitative PCR was performed using StepOne plus systems 
(Applied Biosystems, Foster City, California, USA) with a SensiFAST 
SYBR Hi-ROX kit (Bioline). All RNA-level expressions were calculated 
using the ∆∆Ct method and normalized to GAPDH. The sequences of the 
sense (Forward; F) and antisense (Reverse; R) primers were as follows;  
BACE-F (5`-GATGGTGGSCAACCTGAG-3`), BACE-R (5`-CTGGTA-
GTAGCGATGCAG-3`), TACE-F (5`-ATCTGAAGAGTTTGTTCGTCG-
AG-3`), TACE-R (5`-TCCACGGCCCATGTATTTAT-3`), ADAM10-F (5`-
CCATGCTCATGGAAGACAGTT-3`), ADAM10-R (5`-CCTTCTTCACC-
ATAAATATGTCCA-3`), Nampt-F (5`-GGTCATCTCCCGATTGAAGT-3`), 
Nampt-R (5`-TCAATCCAATTG-GTAAGCCA-3`), GAPDH-F (5`-GGC-
ATTGCTCTCAATGACAA-3`) and GAPDH-R (5`-ATGTAGGCCATGA-
GGTCCAC-3`).  
 
 
 
	 26	
6. Enzyme-linked Immunosorbent Assay 
 
     The quantitative assessment of Aβ1-42 of secretion was performed using 
the Human Amyloid β42 ELISA (HS) High sensitivity Kit (EMD Millipore 
Corp. MA. USA) according to manufacturer`s instruction. N2A-APP695 cells 
were cultured in 6well plate and treated metformin and donepezil for 24hr, 
and 100ul of culture medium was used for measurement. All results are 
normalized to the value of protein assay with BCA protein Assay Kit 
(Thermo) using cell lysates. 
 
 
7. NAD/NADH ratio measurements 
 
     The measurement of NAD/NADH ratio was performed with whole cell 
extracts of Neuro2A cells using the NAD/NADH Quantitation kit 
(Biovision, Milpitas, CA, USA) according to the manufacturer`s instruction. 
This colorimetric assay measured NADt, which was the sum of NAD and 
NADH, and NADH only. So I could calculate the value of NAD with NADt 
and NADH levels. All assays were measured at 450nm absorbances. All 
values of NAD and NADH were normalized to the protein content of the cell 
lysate determined using the Pierce BCA Protein Assay kit (Thermo). 
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8. SIRT1 activity assay 
 
     Cells were lysed as described in Western blot analysis. After 
measurement of proteins, 10ug of total protein was used in SIRT1 activity 
assay using Colorimetric SIRT1 Activity Assay Kit (Abcam) according to 
the manufacturer`s instruction. The kit included specific substrate that was 
deacetylated by SIRT1, and measured the levels of deacetylation with 
specific antibody. Each sample was performed via triplet assay and the 
values are calculated on average and compared to control value.  
 
 
9. Statistical Analysis 
 
     All results are expressed as the mean ± S.E. All data were analyzed with 
Student’s t-test and one-way ANOVA followed by Dunnett post hoc test. 
Significance was set at P value less than 0.05. 
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III. RESULTS 
 
1. Metformin increases BACE1 expression via AMPK 
 
     I first examined the effects of metformin-induced AMPK activation on 
BACE1 expression in Neuro2A cells. The protein and mRNA levels of 
BACE1 were significantly elevated at 10mM treatment of metformin (Fig 6-
A and B). Also I found that the treatment of 10mM metformin increased 
phosphorylation of AMPK (Fig. 6-A). However, cotreatment of compound 
C, an AMPK inhibitor, with metformin suppressed BACE1 upregulation 
(Fig. 6-C and D), suggesting that metformin-induced BACE1 upregulation is 
AMPK dependent. Next, to confirm that the production of Aβ is indeed 
affected by metformin-induced BACE1 expression, I measured the amount 
of secreted Aβ in culture medium of N2A-APP695 stable cell lines treated 
with metformin by ELISA. As expected, ELISA results showed that the 
secretion level of Aβ was significantly increased at 10mM metformin 
treatment (Fig. 6-E).  
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Figure 6. Metformin increases BACE1 expression. (A) BACE1 
protein levels and AMPK activation levels were determined using 
Western blot analysis. (B) BACE1 mRNA levels were measured by 
qRT-PCR. Neuro2A cells were treated with multiple dose of metformin 
(MET) for 24hr. (C, D) Neuro2A cells were exposed with Compound 
C (CC) for 6hr after 10mM metformin treatment. BACE1 protein 
levels and mRNA levels were analyzed with western blotting and qRT-
PCR. (E) Extracellular Aβ in N2A-APP695 cells was measured using 
ELISA.  *P<0.05 and ***P<0.001 compared with control (CTL).  
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2. Metformin decreases TACE expression while increasing BACE1 
 
     In Aβ synthesis, cleavage of APP via BACE1 was the first and critical 
step.20 However, cleavage APP via α-secretase prevented the Aβ production, 
and these two events occur competitively. The representative α-secretases 
are “a disintegrin and metalloproteinase” (ADAM) family, especially 
ADAM10 and TACE, that cleaved specific site of APP to make non-
amyloidogenic fragments.22 I therefore assessed ADAM10 and TACE 
expression levels in Neuro2A cells, and found that metformin reduced 
protein and mRNA levels of TACE (Fig. 7-A and B). To confirm in vivo 
results, I analyzed the expression levels of α- and β-secretases in the 
hippocampal tissues of db/db mice treated with metformin (2mg/ml, 7days) 
in drinking water. Increase in BACE1 expression and decrease in TACE 
expression also were identified in vivo (Fig. 7-C and D). These results 
showed that metformin affects TACE as well as BACE1 expressions, and 
eventually promote AD-related pathogenesis. 
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Figure 7. Metformin decreases TACE expression in vitro and in 
vivo. (A-B) Metformin-induced α-secretases (ADAM10 and 
TACE) expressions were analyzed western blot and qRT-PCR. (C-
D) The hippocampi of db/db mice (8 week-old, n=3) treated 
2mg/ml of metformin for 7days were used for analyze of 
expression of α- and β-secretases.  All mice were fed metformin on 
water ad libitum. *P<0.05 compared with control (CTL).  
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3. Metformin decreases activity and expression of SIRT1 by reducing 
NAD/NADH ratio 
 
     The activation of AMPK can lead to activation of SIRT1. Activation of 
both AMPK and SIRT1 then can reduce BACE1 expression level and Aβ 
production.78,79 Nevertheless, the previous study and data from the current 
study demonstrated that metformin increased BACE1 expression via AMPK 
activation in neurons. Therefore, I sought to the effect of metformin on 
SIRT1 in neuro2A cells. Protein level of SIRT1 was decreased by metformin 
in Neuro2A cells (Fig. 8-A). Furthermore, metformin significantly 
suppressed activity of SIRT1 at 10mM (Fig. 8-b), the same concentration at 
which metformin increased BACE1 expression and AMPK activation (Fig. 
6-A and B). These data revealed that, in neurons, metformin decreased the 
expression and activity of SIRT1 in contrast with previous findings with 
other peripheral tissues. AMPK is known to activate SIRT1 by increasing 
NAD/NADH ratio.73,75,80 So I measured NAD level and NAD/NADH ratio in 
Neuro2A cells exposed to metformin. Metformin reduced the level of NAD 
and NAD/NADH ratio (Fig. 8-C). Taken together, these results suggested 
that metformin reduces SIRT1 activity via reducing NAD/NADH ratio 
despite AMPK activation in neurons.  
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Figure 8. Metformin decreases SIRT1 activity and expression.  (A) 
Metformin-induced changes in SIRT1 expression was analyzed using 
western blot.  (B) SIRT1 activity was measured using SIRT1 activity 
kit at 1mM and 10mM metformin treatment. (C) The cellular levels of 
NAD and NADH were evaluated at 450nm. All experiments were 
performed at 24hr treatment condition and were repeated three times. 
*P<0.05 and **P<0.01 compared with control (CTL).  
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4. Metformin-induced Nampt suppression accounts for reduced SIRT1 
activity and NAD levels 
 
     SIRT1 has been reported to be activated through AMPK/Nampt/NAD 
pathway.81 Inhibition of Nampt decreases the cellular level of NAD.82 
However, results from the current study showed that the expression and 
activity of SIRT1 was decreased despite the activation of AMPK by 
metformin. I then asked whether metformin affects the levels of α- and β-
secretases via Nampt. First, I examined the effect of metformin on Nampt 
expression. In Western blot analysis and qRT-PCR, expression level of 
Nampt was decreased upon metformin treatment (Fig. 9-A and B). Next, I 
observed the changes in BACE1 and TACE levels upon Nampt 
overexpression in Neuro2A cells. Although Nampt was reduced by 
metformin even in overexpression condition, BACE1 and TACE levels were 
unaffected by metformin (Fig. 9-C and D). These results suggest that 
sufficient amount of Nampt could suppress metformin-induced aberrations 
in Aβ metabolism by supplying NAD needed to SIRT1 activation. 
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Figure 9. Metformin decreases Nampt expression. (A) Metformin-
induced Nampt expression was analyzed using western blot. (B) 
Nampt mRNA expression was measured using qRT-PCR upon 10mM 
metformin treatment. (C-D) In Nampt overexpression condition, 
BACE1 and TACE expressions were analyzed by western blot and 
qRT-PCR. All experiments were performed at 24hr treatment 
condition and were repeated three times. *P<0.05 and **P<0.01 
compared with control (CTL). #P<0.05 and ##P<0.01 compared with 
metformin (MET 10mM). 
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5. Donepezil reverses metformin-induced TACE suppression via 
Nampt/NAD/SIRT1 in vitro and in vivo 
 
     Donepezil is the most widely prescribed anti-dementic drug, which has 
been also identified as an AMPK activator.83 I thus intended to examined if 
donepezil could suppress (as an anti-dementic drug) or aggravate (as an 
AMPK activator) the observed adverse effects of metformin on neurons. 
First, I analyzed the amount of secreted Aβ using ELISA in Neuro2A cells 
treated metformin alone and metformin plus donepezil. Interestingly, Aβ was 
reduced upon the cotreatment compared to treatment of metformin alone 
(Fig. 10-A). I also examined the changes in the levels of secretases, and 
found that expression levels of secretases were reversed by donepezil 
cotreatment compared to metformin alone (Fig. 10-B and C). Especially, 
mRNA levels of BACE1 and TACE were significantly changed towards the 
direction of reducing Aβ production. Next, I investigated whether donepezil 
regulates Nampt/SIRT1 pathway as well. In donepezil cotreatment 
condition, NAD level and Nampt expression were increased (Fig. 10-B to 
D), while SIRT1 expression was not changed (data was not shown), 
suggesting that donepezil might enhance the activity of SIRT1 via 
Nampt/NAD pathway. Thus, I aimed to confirm the involvement of Nampt 
in actions of donepezil by using FK866, a Nampt inhibitor. FK866 mitigated 
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the effects of donepezil on mRNA levels of TACE (Fig. 10-E and F). Finally, 
I intended to confirm the effect of donepezil in vivo. I treated db/db mice for 
7days with either of donepezil (5mg/kg) plus metformin (2mg/ml) or 
metformin alone. The reason for use of db/db mice was to recapitulate the 
context-relevant situations in real clinical realms where metformin is 
prescribed. I found that donepezil also reversed adverse effects of metformin 
on BACE1 and TACE expression in the hippocampal tissues of db/db mice 
(Fig. 11-A and B). Taken together, these results suggest that donepezil 
treatment could be an effective option to suppress the adverse effects of 
metformin on TACE and BACE1 expression via Nampt/NAD/SIRT1 
pathway.  
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Figure 10. Donepezil reverses metformin-induced amyloidogenesis 
in vitro. (A) Conditioned medium of Neuro2A cells that were treated 
with 10mM metformin (MET) and 20uM donepezil (DN) for 24hr were 
used for measurement of secretion of Aβ via ELISA. (B) Protein levels 
of α- and β-secretases of which Neuro2A cells were treated metformin 
(10mM) and donepezil (20uM) for 24hr were determined using western 
blot. (C) BACE1 and TACE mRNA levels were measured using qRT-
PCR. (D) The cellular NAD level and NAD/NADH ratio were evaluated 
using NAD/NADH Assay Kit. (E-F) The TACE expressions of Neuro2A 
cells treated with10mM metformin, 20uM donepezil and 10nM FK866 
(FK) were measured by Western blot and qRT-PCR. *P<0.05, **P<0.01 
and ***P<0.001 compared with control (CTL). #P<0.05 and ##P<0.01 
compared with metformin (MET 10mM). %P<0.05 compared with 
cotreatment of metformin and donepezil (MET+DN). 
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Figure 11. Donepezil reverses metformin-induced amyloidogenesis 
in vivo. (A-B) The expressions of α- and β-secretases of hippocampi in 
which db/db mice (n=3) were treated donepezil (5mg/kg) with 
metformin for 7days were analyzed using Western blot and qRT-PCR. 
*P<0.05 and **P<0.01 compared with control (CTL). #P<0.05 
compared with metformin (MET 10mM).  
NAMPT
!-Actin
BACE1
TACE
CTL MET MET+DN CTL MET MET+DN
0
50
100
150
200
B
A
C
E1
 / 
β-
ac
tin
(%
 o
f C
TL
)
*
CTL MET MET+DN
0
50
100
150
TA
C
E 
/ β
-a
ct
in
(%
 o
f C
TL
)
CTL MET MET+DN
0.0
0.5
1.0
1.5
2.0
2.5
B
A
C
E1
 m
R
N
A
 le
ve
l
(R
el
at
iv
e 
to
 C
TL
)
** #
CTL MET MET+DN
0.0
0.5
1.0
1.5
2.0
TA
C
E 
m
R
N
A
 le
ve
l
(R
el
at
iv
e 
to
 C
TL
)
#
A
B
ampt
	 40	
IV. DISCUSSION 
 
     The role of metformin, having been primarily used for DM over the past 
50yr,45 has been still controversial regarding AD-related pathologies. In 
various mechanistic studies, actions of metformin have been related to its 
ability to activate AMPK.84 In addition, a recent study has shown that 
metformin can activate SIRT1 independently of AMPK pathway in 
hepatocytes.80 Many previous studies reported that the activations of both 
AMPK and SIRT1 are beneficial for energy metabolism in various organs 
including the brain.61,85,86 Whereas, metformin was reported to increase of 
Aβ via upregulation of BACE1 in neurons. Therefore, I confirmed that 
metformin increases BACE1 expression and Aβ production via AMPK in 
neurons, consistent with previous findings.59 Contrary to previous finding 
from other peripheral tissues,86 I found that metformin decreased the 
expression and activity of SIRT1 via suppression of Nampt/NAD pathways 
even while activating AMPK. I found that AMPK activation without SIRT1 
activation by metformin caused amyloidogenesis in neurons (Fig. 12-A). 
Additionally, I identified that donepezil could reverse the adverse effects of 
metformin within the framework of translational research using diabetic 
model mice (Fig. 12-B).  
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Figure 12. Working hypothesis for actions of metformin and 
donepezil in amyloidogenesis. (A) Metformin can activate only 
AMPK but fails to activate SIRT1 due to its inhibitory action on 
Nampt. This action results in enhancement of amyloidogenic pathway 
leading to both increase in BACE1 and decrease in TACE. (B) 
Donepezil increases Nampt so that AMPK and SIRT1 can work 
concomitantly, leading to enhancement of non-amyloidogenic pathway.  
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     The cerebral aggregation of Aβ is one of main pathogenic events in AD.17 
Aβ is generated from APP by actions of two enzyme, BACE1 and γ-
secretase.14,20 In contrast to BACE1, α-secretases, such as ADAM10 and 
TACE, forestall Aβ production through cleavage of APP at other specific site 
(Fig. 2).21,22 The result of this study showed that metformin can augment the 
production of Aβ via not only increasing BACE1 but also decreasing TACE. 
I also measured ADAM10 protein and mRNA level. ADAM10 expression 
was not significantly changed by metformin treatment (Fig. 7-A and B). 
Recently, TACE has also been focused on regarding Aβ metabolism.87,88 
Yoshida et al. showed that activating TACE via SIRT1 suppressed the 
production of Aβ in human astrocytoma cells.89 Above these previous 
reports, findings from the current study also suggest that metformin reduced 
TACE via suppression of Nampt was important in amyloidogenesis.  
 
     In a previous study, Chen et al. showed only increment of BACE1 via 
AMPK activation. In fact, the role of AMPK was controversial in neurons. 
AMPK activation could increase the tau phosphorylation.18 Additionally, it 
was reported that tau phosphorylated by AMPK mediates synaptotoxic 
effects of Aβ oligomers.28 I demonstrated that metformin increases 
amyloidogenesis in neurons via inactivation of SIRT1 by Nampt suppression 
while AMPK was activated (Fig. 7 and 8) .  
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     Finally, I intended to see if an anti-dementic drug could offset adverse 
effects of metformin as a translational approach. Donepezil, the 
acetylcholinesterase inhibitor, is being most widely prescribed for AD 
patients worldwide. Donepezil reduced Aβ induced-neurotoxicity via GSK-
3β,90 and decreased Aβ plaque density.91 Data from the current study showed 
that donepezil suppresses the Aβ secretion increased by metformin in vitro 
(Fig. 10-A). Interestingly, donepezil significantly enhanced the levels of 
NAD and expression of TACE (Fig. 10-C and D). Upon treatment of FK866, 
an Nampt inhibitor, donepezil failed to increase TACE expression (Fig. 10-E 
and F), indicating that Nampt is participated in non-amyloidogenic 
mechanism via donepezil. Moreover, I confirmed that donepezil could 
reverse the adverse effect of metformin via modulating BACE1 and TACE 
in vivo (Fig. 11).  
 
     In a previous study, it was identified that β-oxidation, rather than Nampt, 
mediates AMPK-induced enhancement in NAD/SIRT1 pathway in the 
skeletal muscle cells.55 However, considering that β-oxidation is not favored 
energy metabolism in neurons, metformin-mediated suppression of Nampt 
could be the main reason for the failure of SIRT1 activation in neurons upon 
AMPK activation. Current experiments used db/db mice, a well-defined 
diabetic model, considering that metformin is an anti-diabetic medication. In 
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previous studies, diabetic mice have been used to examine the effects of 
diabetes on Aβ secretion, tau protein level and cognitive function.59,92 
However, for I only examined short-term effects of treatment of medications 
(for 7days), long-term experiments are further required to confirm the 
translational meanings of findings from this study, since diabetic patients 
need to take medicines for a long time.  
 
     Results from the current study demonstrated that metformin suppressed 
neuronal Nampt expression which is crucial for SIRT1 activation. Moreover, 
to the best of my knowledge, this is the first thesis demonstrating that 
metformin reduced TACE via suppression of Nampt. Although I did not 
investigate the interaction of metformin and γ-secretase, metformin-
mediated decrease in TACE expression was confirmed as reason for the 
increase in amyloidogenesis by this drug in addition to BACE1 upregulation. 
Finally, these results about cotreatment of metformin and donepezil 
suggested the possibility of pharmacological modulations that prevent the 
adverse effect of metformin in neurons. 
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V. CONCLUSION 
 
     This study identified that Nampt was the critical target of metformin-
induced adverse effects on amyloidogenic pathway. Also, I showed that 
donepezil could reverse the metformin-induced negative effects in neurons. 
What I have found through this study is, 
 
1. Metformin activated AMPK, however reduced Nampt in neurons. 
 
2. Metformin-mediated suppression of Nampt caused a decrease in 
SIRT1 activity, and so the failure in the concomitant action of 
AMPK and SIRT1. 
 
3. AMPK activation without SIRT1 activation increased BACE1 
expression and decreased TACE1 expression, which increased 
amyloidogenesis.  
 
4. Donepezil could reverse the adverse effects of metformin on 
amyloidogenic pathway by rendering possible the concomitant 
action of AMPK and SIRT1 via enhancing Nampt expression. 
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ABSTRACT (In Korean) 
 
 
Hippocampus 내 아밀로이드 생성과 비생성 경로에서의  
nicotinamide phosphoribosyltransferase 의 관여 기전 
 
< 지도교수 : 김 어 수 > 
 
연세대학교 대학원 의과학과 
 
정 지 현 
 
 
   최근 신경세포에서 metformin 의 AMP-activated kinase (AMPK) 
활성화가 Alzheimer`s disease(AD)와 관련, 아밀로이드 생성 기전 
활성을 유발하는 것으로 보고되었다. 1950 년대부터 2 형당뇨의 
1 차약제로 사용되고 있는 Metformin 의 주요기전은 AMPK 를 활성화 
시켜 포도당 생성 억제, 포도당 흡수촉진 및 나아가 대사증후군 
억제를 하는 것으로 알려져 있다. 기존 말초조직의 연구에서 
AMPK 의 활성화는 Nicotinamide phosphotransferase (Nampt)/NAD 
기전을 통하여 silent mating-type information regulator 2 homolog 1 
(SIRT1) 의 활성화를 유도, AMPK-SIRT1 동시작용을 유도하는 
것으로 보고되어 있다. AMPK 와 SIRT1 의 동시작용은 생체 에너지 
항상성과 관련하여 다양한 효능이 있는 것으로 알려져 있다. 또한, 
최근 연구를 통하여 간조직에서  metformin 은 SIRT1 을 활성화 
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시키는 것으로 보고되었다. 본 연구에서는 신경세포에서 
metformin 이 AMPK 를 활성화 시킴에도 불구하고 아밀로이드 생성 
경로에서의 부정적 효과를 가져오는 원인과 해결 방법을 찾고자 
하였다. 우선적으로 신경모세포종에서 metformin 에 의한 세포 내 
SIRT1 의 활성화 및 발현의 억제를 발견하였다. 그리고, SIRT1 
활성 억제 원인으로 metformin 의 Nampt 감소에 따른 신경세포 내 
NAD 공급을 억제하기 때문인 것으로 확인하였다. 또한, 
metformin 이 beta-site amyloid precursor protein cleavage enzyme 1 
(BACE1) 을 증가시켜 아밀로이드 생성 경로를 활성시키는 것 외에, 
Nampt 감소를 통하여 tumor necrosis factor alpha converting enzyme 
(TACE) 발현을 억제, 아밀로이드 비생성 경로를 억제하는 
것을 Nampt 과발현 세포 모델을 통하여 검증하였다. 마지막으로 
중개연구의 관점에서 세포 및 동물 모델을 통하여 donepezil 이 
metformin 의 신경독성을 억제하는 결과를 확인하였다.  
   본 연구는 metformin 의 치매병리에서의 신경 독성 유발 관련, 
SIRT1 과 Nampt 를 통하여 에너지 대사의 측면에서 신경세포의 
특이성과 그 원인을 밝혔다. 그리고 metformin 에 의한 아밀로이드 
생성경로의 주요 타겟으로서 BACE1 외에 TACE 가 관련됨을 
규명하였다. 또한, donepezil 이 metformin 복용으로 인한 치매 
병리의 발병을 억제할 수 있는 가능성을 가지고 있음을 
보여줌으로서 metformin 의  신경세포 내 부작용의 원인 및 그 해결 
방법을 제시하는 데 본 연구의 중요한 의의가 있다고 본다. 
 
핵심되는 말: Nampt, SIRT1, AMPK, Aβ, Amyloidogenesis, Metformin, 
BACE1, TACE, Donepezil 
